InnovFin Infectious Diseases
Programme aimed at supporting preclinical innovative solutions to infectious diseases
European Investment Bank (EIB)
Loans and equity
EUR 7.5 million to EUR 75 million, depending on project
Innovative players active in developing innovative vaccines, drugs, medical and diagnostic devices or novel research infrastructures for combatting infectious diseases.
- The promoter should be a large pharmaceutical company, a mid-cap or a small and medium-sized enterprise (SME), a research institute/organisation, a university, a non-profit entity or a special-purpose vehicle (SPV).
- Promoters, sponsors and/or operators must be willing to substantially co-fund the project.
- The beneficiary must be established and operating in one or several of the Member States and Horizon 2020 Associated Countries.
Pre commercial stage investments – Project costs may include clinical trial costs, set-up of commercialisation such as market access, development of prototypes or industrial roll-out of novel equipment, pre-clinical R&D costs and working capital requirement.
The project and/or the intellectual property (IP) development (e.g. clinical trials) can be undertaken outside Member States and Horizon 2020 Associated Countries.